TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Mesoblast ( (MESO) ) just unveiled an update.
On October 20, 2025, Mesoblast Limited reported a significant increase in revenues for the quarter ended September 30, 2025, driven by the adoption of Ryoncil®, which saw a 69% increase in net sales. The assignment of a permanent J-Code by CMS on October 1, 2025, is expected to further enhance product adoption. Mesoblast has onboarded 40 transplant centers and expanded coverage to over 260 million US lives. The company plans a pivotal trial for Ryoncil® in adults with severe SR-aGvHD, aiming to extend its label to a larger population. Mesoblast’s financial position remains strong with $145 million in cash and new funding options.
The most recent analyst rating on (MESO) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on Mesoblast stock, see the MESO Stock Forecast page.
Spark’s Take on MESO Stock
According to Spark, TipRanks’ AI Analyst, MESO is a Neutral.
Mesoblast’s overall stock score reflects a company with strong technical momentum and promising growth prospects, particularly with the successful launch of Ryoncil. However, financial performance challenges and valuation concerns due to ongoing losses weigh on the score.
To see Spark’s full report on MESO stock, click here.
More about Mesoblast
Mesoblast Limited is a global leader in developing allogeneic cellular medicines for severe inflammatory conditions. The company focuses on therapies derived from mesenchymal lineage cell technology, which release anti-inflammatory factors to modulate the immune system. Mesoblast’s Ryoncil® is the first FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft-versus-host disease. The company is also developing therapies for other inflammatory diseases and has commercial partnerships in Japan, Europe, and China.
Average Trading Volume: 241,195
Technical Sentiment Signal: Strong Buy
Current Market Cap: $2.21B
For detailed information about MESO stock, go to TipRanks’ Stock Analysis page.